拉考沙胺治疗危重症患者急性复发性癫痫发作和周期性癫痫样放电。
Lacosamide in the treatment of acute recurrent seizures and periodic epileptiform patterns in critically ill patients.
机构信息
The Edward B. Bromfield Epilepsy Program, Brigham and Women's Hospital, Division of Epilepsy, EEG, and Sleep Neurology, Department of Neurology, Harvard Medical School, Boston, MA 02115, USA.
出版信息
Epilepsy Behav. 2011 Jan;20(1):48-51. doi: 10.1016/j.yebeh.2010.10.012. Epub 2010 Nov 19.
We investigated the safety, tolerability, and effectiveness of lacosamide (LCM) in patients with acute recurrent seizures or with periodic epileptiform activity captured during continuous EEG monitoring. A total of 17 patients received LCM; 12 patients received LCM as a second or third antiepileptic drug (AED), one patient as a fourth AED, and one patient as a fifth AED. No additional AEDs were introduced after LCM in 15 patients. Twelve patients responded to LCM with improvement in the seizures or periodic epileptiform activity. Two patients required further AED management or burst suppression. No adverse effects, including symptomatic bradycardia and allergic reactions, were seen for intravenous infusion dosages up to 300 mg. Eleven patients were eventually discharged on LCM. LCM is an important new AED in the add-on treatment of acute recurrent seizures and periodic epileptiform activity in critically ill patients.
我们研究了拉考酰胺（LCM）在急性复发性癫痫或在连续脑电图监测期间捕获的周期性癫痫样活动患者中的安全性、耐受性和有效性。共有 17 名患者接受了 LCM 治疗；12 名患者将 LCM 作为第二种或第三种抗癫痫药物（AED），一名患者作为第四种 AED，一名患者作为第五种 AED。在 15 名患者中，LCM 后没有引入其他 AED。12 名患者对 LCM 有反应，癫痫发作或周期性癫痫样活动得到改善。两名患者需要进一步的 AED 管理或爆发抑制。静脉输注剂量高达 300mg 时，未观察到任何不良反应，包括症状性心动过缓和过敏反应。11 名患者最终出院时使用了 LCM。LCM 是一种新的重要的添加型抗癫痫药物，可用于治疗重症患者的急性复发性癫痫和周期性癫痫样活动。
Zotero 插件